Recombinant proteins for medical use: the attractions and challenges.
Recombinant proteins that have survived the challenges of process development and clinical trials are becoming blockbuster medical products. Growth factors, enzymes and antibodies are being improved by mutational approaches, fused with other proteins, and even chemically modified in vitro. Drug development and testing approaches have advanced, and proteins produced in transgenic animals are new becoming available. Future protein products might include cancer vaccines and therapies for a variety of genetic diseases, but alternative treatments involving gene therapy or small synthetic compounds will provide competition.
Chiron Corporation, Emeryville, USA.
K
K
Koths
D000818:Animals; D001709:Biotechnology; D003001:Cloning, Molecular; D004345:Drug Industry; D015870:Gene Expression; D006801:Humans; D015202:Protein Engineering; D017510:Protein Folding; D011994:Recombinant Proteins / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use
D011994:Recombinant Proteins; D014614:Vaccines, Synthetic